Research ArticleArticle
An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users
Amy H. Warriner, Ryan C. Outman, Jeroan J. Allison, Jeffrey R. Curtis, Nathan J. Markward, David T. Redden, Monika M. Safford, Eric J. Stanek, Amy R. Steinkellner and Kenneth G. Saag
The Journal of Rheumatology July 2015, jrheum.141238; DOI: https://doi.org/10.3899/jrheum.141238
Amy H. Warriner
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Ryan C. Outman
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Jeroan J. Allison
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Jeffrey R. Curtis
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Nathan J. Markward
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
David T. Redden
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Monika M. Safford
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Eric J. Stanek
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Amy R. Steinkellner
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Kenneth G. Saag
From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA. Funding provided by the American College of Rheumatology Research and Education Foundation. A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation. Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu. Accepted for publication April 29, 2015.
Article Information
jrheum.141238
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online July 1, 2015.
Article Versions
- You are currently viewing a Latest version of this article (July 1, 2015 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2015 The Journal of Rheumatology
Author Information
- Amy H. Warriner,
- Ryan C. Outman,
- Jeroan J. Allison,
- Jeffrey R. Curtis,
- Nathan J. Markward,
- David T. Redden,
- Monika M. Safford,
- Eric J. Stanek,
- Amy R. Steinkellner and
- Kenneth G. Saag
- From the Division of Endocrinology, Diabetes and Metabolism, and Division of Clinical Immunology and Rheumatology, and Department of Biostatistics, and Division of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama; Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, Massachusetts; Express Scripts, St. Louis, Missouri; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; Real Endpoints LLC, Westport, Connecticut, USA.
Funding provided by the American College of Rheumatology Research and Education Foundation.
A.H. Warriner, MD, Division of Endocrinology, Diabetes and Metabolism; R.C. Outman, MS, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; J.J. Allison, MD, MS, Department of Quantitative Health Sciences, University of Massachusetts Medical School; J.R. Curtis, MD, MS, MPH, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; N.J. Markward, PhD, Express Scripts; D.T. Redden, PhD, Department of Biostatistics; M.M. Safford, MD, Division of Preventive Medicine, University of Alabama at Birmingham; E.J. Stanek, PharmD, Novartis Pharmaceuticals Corporation; A.R. Steinkellner, PharmD, Express Scripts*, and Real Endpoints LLC; K.G. Saag, MD, MSc, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham. * Affiliation at the time of study and manuscript preparation.
Address correspondence to Dr. K.G. Saag, The University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, 820 Faculty Office Tower, 510 20th St. South, Birmingham, Alabama 35294, USA. E-mail: ksaag@uab.edu, kenneth.saag@ccc.uab.edu.
Accepted for publication April 29, 2015.
Article usage
Statistics from Altmetric.com
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users
Amy H. Warriner, Ryan C. Outman, Jeroan J. Allison, Jeffrey R. Curtis, Nathan J. Markward, David T. Redden, Monika M. Safford, Eric J. Stanek, Amy R. Steinkellner, Kenneth G. Saag
The Journal of Rheumatology Jul 2015, jrheum.141238; DOI: 10.3899/jrheum.141238
An Internet-based Controlled Trial Aimed to Improve Osteoporosis Prevention among Chronic Glucocorticoid Users
Amy H. Warriner, Ryan C. Outman, Jeroan J. Allison, Jeffrey R. Curtis, Nathan J. Markward, David T. Redden, Monika M. Safford, Eric J. Stanek, Amy R. Steinkellner, Kenneth G. Saag
The Journal of Rheumatology Jul 2015, jrheum.141238; DOI: 10.3899/jrheum.141238